Overall survival (OS) for Stage IV lung ADC at initial diagnosis were analyzed in patients with BRAF V600E or with undetected mutation (no driver mutation/fusion detected in BRAF, EGFR, KRAS, ALK, ROS1, RET, HER2, or MET genes) (Figure 3b). This evidence concerns the gene MET and medical procedure.